Monthly Archives: September 2020

From natural killer cells to off-the-shelf CAR-Ts, biopharma targets cancer with next-gen cell therapies

This month, Tmunity Therapeutics is dosing the first patients who have enrolled in an early clinical trial testing an engineered CAR-T immune cell therapy for metastatic prostate cancer. The trial’s start is notable, and not just because it’s been challenging to recruit patients for cancer trials during the COVID-19 pandemic. The experimental CAR-T is among the first cell therapies to target a solid tumor—an enemy that was once considered too difficult to tackle with that type of treatment.

More >>

Acepodia Strengthens Management Team with Appointments of Biotech Industry Veterans

SAN FRANCISCO and TAIPEI, Taiwan, Sept. 01, 2020 (GLOBE NEWSWIRE) — Acepodia, a biotechnology company developing next generation solid tumor and blood-based cancer cell therapies, today announced key appointments to its business and clinical development teams. Mark J. Gilbert, M.D., a cell therapy pioneer, joins as senior vice president of Research and Development and will lead early-stage research efforts to advance the company’s proprietary, potent and off-the-shelf cell therapies from
exploratory development stages into clinical trials.

More >>